The European Society of Medical Oncology (ESMO) annual congress was held September 26-30 in Barcelona, Spain.
Journal of Clinical Pathways was onsite to provide coverage of the most relevant and important sessions of the meeting.
George W Sledge, MD, professor of medicine, Stanford University School of Medicine, shares overall survival results from the MONARCH 2 trial.
Aude Fourcade, researcher at Gustave Roussy, highlights an effort to to determine a definitive number of quality indicators and the importance of such indicators to assess and validate clinical pathways.
Yara Abdou, MD, details how a novel machine learning-assisted prognostication method based on genomic expression in the tumor microenvironment can further personalize breast cancer management.
Andrew Bottomley, PhD, European Organization for Research and Treatment of Cancer, speaks to whether value frameworks such as the ESMO MCBS can contribute to higher patient quality of life and to the international standards for analyzing quality of life.
A neoadjuvant combination regimen consisting of immunotherapy and chemotherapy provides greater anti-tumor activity than chemotherapy alone in patients with early-stage triple-negative breast cancer, according to new research.
A post-hoc analysis of the IMpassion130 study evaluated the concordance of multiple PD-L1 immunohistochemistry assays and their ability to predict clinical activity in unresectable, advanced or metastatic triple-negative breast cancer.
Significant Improvement in OS With CDK4/6 Inhibitor, Fulvestrant Combination in Women with HR+, HER2- Advanced Breast Cancer
A study presented at the ESMO Annual Congress showed that abemaciclib plus fluvestrant demonstrated a statistically significant improvement in overall survival in the Phase 3 MONARCH 2 clinical trial.
Researchers analyzed the prognostic factors that influence outcomes after therapy in relapsed or refractory Hodgkin lymphoma.
The combination of a PARP inhibitor with front-line combination chemotherapy and continued PARP inhibitor maintenance significantly extends PFS in patients with newly diagnosed ovarian serous carcinoma, according to new research.
A radiomics signature from a Spanish oncology institute combines radiomics and clinical data to predict response to immunotherapy with high specificity in patients with advanced solid tumors.
Men with prostate cancer can be spared radiotherapy after surgery, according to presentations of the RADICALS-RT trial and a meta-analysis.
A study showed “clinically meaningful improvements” in survival and response rates for first-line immunotherapy compared with standard-of-care therapy for advanced HCC.